194 related articles for article (PubMed ID: 28124585)
1. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
Decourt B; Drumm-Gurnee D; Wilson J; Jacobson S; Belden C; Sirrel S; Ahmadi M; Shill H; Powell J; Walker A; Gonzales A; Macias M; Sabbagh MN
Curr Alzheimer Res; 2017; 14(4):403-411. PubMed ID: 28124585
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
[TBL] [Abstract][Full Text] [Related]
4. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
8. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and immunogenicity of an active anti-Aβ
Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease.
Farlow MR; Thompson RE; Wei LJ; Tuchman AJ; Grenier E; Crockford D; Wilke S; Benison J; Alkon DL
J Alzheimers Dis; 2019; 67(2):555-570. PubMed ID: 30530975
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
[TBL] [Abstract][Full Text] [Related]
13. A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's Disease.
Malpas CB; Vivash L; Genc S; Saling MM; Desmond P; Steward C; Hicks RJ; Callahan J; Brodtmann A; Collins S; Macfarlane S; Corcoran NM; Hovens CM; Velakoulis D; O'Brien TJ
J Alzheimers Dis; 2016 Jul; 54(1):223-32. PubMed ID: 27447428
[TBL] [Abstract][Full Text] [Related]
14. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
17. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial.
Hannestad J; Duclos T; Chao W; Koborsi K; Klutzaritz V; Beck B; Patel AK; Scott J; Thein SG; Cummings JL; Kay G; Braithwaite S; Nikolich K
J Alzheimers Dis; 2021; 81(4):1649-1662. PubMed ID: 33967047
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Fujino T; Yamada T; Asada T; Tsuboi Y; Wakana C; Mawatari S; Kono S
EBioMedicine; 2017 Mar; 17():199-205. PubMed ID: 28259590
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
Wilkinson D; Windfeld K; Colding-Jørgensen E
Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]